Clinical Trials Logo

Glioblastoma Multiforme clinical trials

View clinical trials related to Glioblastoma Multiforme.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT06404034 Available - Glioblastoma Clinical Trials

Expanded Access to Gallium Maltolate (GaM)

Start date: n/a
Phase:
Study type: Expanded Access

The objective of this program is to provide GaM for compassionate use in patients with relapsed/refractory histologic or molecular glioblastoma who have exhausted available treatments. The population of this program is adult patients aged greater than or equal to 18 years with a diagnosis of relapsed/refractory histologic or molecular glioblastoma, according to the WHO 2021 diagnostic criteria. Molecular glioblastoma is characterized as an IDH-wildtype diffuse and astrocytic glioma in adults if there is microvascular proliferation or necrosis or TERT promoter mutation or EGFR gene amplification or +7/-10 chromosome copy number changes

NCT ID: NCT05551013 Available - Glioblastoma Clinical Trials

Treatment of Recurrent GBM With APG-157 Via Expanded Access

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access request will evaluate APG-157, a botanical drug under development for other cancers, as potential treatment for recurrent Glioblastoma multiforme (GBM) patients.

NCT ID: NCT02146066 Available - Clinical trials for Glioblastoma Multiforme

Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221

DCVax-L EAP
Start date: n/a
Phase: N/A
Study type: Expanded Access

The study is an open-label expanded access study for patients for whom vaccine was manufactured during the Northwest Biotherapeutics' 020221 DCVax-L for GBM screening process, but who subsequently failed to meet specific enrollment criteria. Patients will receive therapy per investigator discretion (standard of care) as well as active vaccine per the 020221 protocol administration schedule. It is estimated that approximately 99 patients will enroll in this study.